WuXi STA Opens New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers


SHANGHAI, September 9, 2022 /PRNewswire/ — WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new sterile lipid nanoparticle (LNP) formulation development and manufacturing facility at its campus in Wuxi City. Created in response to growing demand for complex injection dosage forms, this new facility marks the company’s rapidly growing parenteral formulation capabilities and provides a new opportunity to help customers develop and deliver better medicines to patients. .

This new facility integrates a multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform, delivering significant advantages in drug loading, liposome particle size and encapsulation efficiency. Additionally, the modular design provides greater processing flexibility, allowing this platform to serve a wide range of manufacturing scales from 10 to 50 L per batch.

As a premier contract research, development and manufacturing organization (CRDMO), WuXi STA’s integrated pharmaceutical platform offers a full range of services, including solid-state development, pre- formulation, formulation development and manufacturing of clinical to commercial pharmaceutical products with a variety of drug delivery technologies, including a wide range of oral and injectable dosage forms. This new sterile LNP platform further extends our end-to-end capabilities.

WuXi STA has 12 locations across the United States, Europe and Asia which offer a wide range of services and meet global regulatory standards. Along with other development and manufacturing sites, this new platform offers considerable synergy with the Company’s CRDMO oligonucleotide platform. The LNP delivery system is particularly advantageous in overcoming the bioavailability challenge of oligonucleotides and their conjugates.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, said, “We are delighted to support our partners with this state-of-the-art LNP facility to meet the growing demand for injection dosage forms. advancements. We will continue to expand the capacity and capabilities of our CRDMO platform to enable our partners to bring more innovative medicines to market faster for patients around the world. »

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life science industry, with global operations. As a premier Contract Research, Development and Manufacturing Organization (CRDMO), WuXi STA provides its global partners with efficient, flexible and high-quality solutions for Integrated Chemistry, Manufacturing and Controls (CMC), preclinical uses to commercial uses, including development and manufacturing. small molecules, oligonucleotides, peptides and various complex chemical conjugates.

For more information, visit: http://www.STApharma.com



Comments are closed.